The GLAUrious consortium aims to complete the final steps in development of the EAGLE device, namely clinical validation of the prototype, commercial prototype production by cost optimization of components, dissemination to key opinion leaders and distributors, and refinement of the commercial strategy. Successful validation of EAGLE will result in its commercialization enabling, on one hand, substantial penetration by this innovative product of the ophthalmic market, and on the other hand boosting growth of the industrial consortium partners.

Last News  

Please reload

  web design: STUDIO81

This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement

No 720274